<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="102">
  <stage>Registered</stage>
  <submitdate>1/08/2005</submitdate>
  <approvaldate>5/08/2005</approvaldate>
  <actrnumber>ACTRN12605000093684</actrnumber>
  <trial_identification>
    <studytitle>Gamma-vitamin E study</studytitle>
    <scientifictitle>Different forms of vitamin E and their effect on risk factors for heart disease in type 2 diabetic subjects. A randomised, double blind, placebo controlled trial.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Risk factors for heart disease in type 2 diabetics</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>6 week parallel intervention, volunteers randomised to either (i) RRR-alpha-tocopherol, (ii) mixed tocopherol (predominately gamma-tocopherol)?</interventions>
    <comparator>Placebo (soybean oil stripped of tocopherols)</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Inflammation</outcome>
      <timepoint>At baseline and following the 6 week intervention</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Oxidative stress (including neutrophil function)</outcome>
      <timepoint>At baseline and following the 6 week intervention</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Cellular enrichment</outcome>
      <timepoint>At baseline and following the 6 week intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood pressure</outcome>
      <timepoint>At baseline and following 6 week intervention.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Vascular function</outcome>
      <timepoint>At baseline and following 6 week intervention.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Type 2 diabetes.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Type 1 diabetes, insulin use, pure vitamin E/tocopherol supplements, NSAIDs, smoking, recent CVD event, renal impairment, BMI&gt;35, high alcohol intake.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomisation done by someone not involved in the study.</concealment>
    <sequence>Subjects were randomised by block randomisation using computer generated random numbers, with no restrictions</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>2/02/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Western Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Western Australia</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A/Prof Kevin D. Croft</name>
      <address>School of Medicine &amp; Pharmacology
University of Western Australia
GPO Box X2213
Perth WA 6847</address>
      <phone>+61 8 92240275</phone>
      <fax>+61 8 92240246</fax>
      <email>kcroft@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Natalie C. Ward</name>
      <address>School of Medicine &amp; Pharmacology 
University of Western Australia
GPO Box X2213
Perth WA 6847</address>
      <phone>+61 8 92240381</phone>
      <fax>+61 8 92240243</fax>
      <email>nward@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>